These PPARγ agonists have been used in the treatment of hyperlipidemia and hyperglycemia and for non-alcoholic steatohepatitis (NASH) and have been proposed for the treatment of CNS diseases. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatohepatitis.